Open Access

Relationship between PDGFR expression and the response to pazopanib in intimal sarcoma of the pulmonary artery: A case report

  • Authors:
    • Satoshi Sai
    • Yoshinori Imamura
    • Naomi Kiyota
    • Naoe Jimbo
    • Masanori Toyoda
    • Yohei Funakoshi
    • Naoko Chayahara
    • Yasuko Hyogo
    • Kei Takenaka
    • Hirotaka Suto
    • Hironobu Minami
  • View Affiliations

  • Published online on: November 9, 2020     https://doi.org/10.3892/mco.2020.2168
  • Article Number: 6
  • Copyright: © Sai et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Intimal sarcoma of the pulmonary artery (PAIS) is a rare disease with a poor prognosis. Pazopanib, which has been indicated in metastatic non‑adipocytic soft‑tissue sarcomas and is expected to be active in PAIS, is a multi‑kinase inhibitor that targets the tyrosine kinase activity of vascular endothelial growth factor receptor (VEGFR), platelet‑derived growth factor receptor (PDGFR) and stem cell factor receptor. The present study reports findings related to two cases of PAIS with PDGF and VEGF expression following treatment with pazopanib. A case with a moderate to strong expression of PDGFR‑α and ‑β presented a long‑term stable disease when treated with pazopanib (progression‑free survival, 5.8 months). In a second case with a weak expression of PDGFR‑α and ‑β, the disease progressed rapidly on pazopanib (progression‑free survival, 1.1 months). VEGFR‑2 was not expressed in the tumors of both cases. The level of PDGFR expression in the tumor tissue may therefore be predictive of pazopanib efficacy.
View Figures
View References

Related Articles

Journal Cover

January-2021
Volume 14 Issue 1

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Sai S, Imamura Y, Kiyota N, Jimbo N, Toyoda M, Funakoshi Y, Chayahara N, Hyogo Y, Takenaka K, Suto H, Suto H, et al: Relationship between PDGFR expression and the response to pazopanib in intimal sarcoma of the pulmonary artery: A case report. Mol Clin Oncol 14: 6, 2021
APA
Sai, S., Imamura, Y., Kiyota, N., Jimbo, N., Toyoda, M., Funakoshi, Y. ... Minami, H. (2021). Relationship between PDGFR expression and the response to pazopanib in intimal sarcoma of the pulmonary artery: A case report. Molecular and Clinical Oncology, 14, 6. https://doi.org/10.3892/mco.2020.2168
MLA
Sai, S., Imamura, Y., Kiyota, N., Jimbo, N., Toyoda, M., Funakoshi, Y., Chayahara, N., Hyogo, Y., Takenaka, K., Suto, H., Minami, H."Relationship between PDGFR expression and the response to pazopanib in intimal sarcoma of the pulmonary artery: A case report". Molecular and Clinical Oncology 14.1 (2021): 6.
Chicago
Sai, S., Imamura, Y., Kiyota, N., Jimbo, N., Toyoda, M., Funakoshi, Y., Chayahara, N., Hyogo, Y., Takenaka, K., Suto, H., Minami, H."Relationship between PDGFR expression and the response to pazopanib in intimal sarcoma of the pulmonary artery: A case report". Molecular and Clinical Oncology 14, no. 1 (2021): 6. https://doi.org/10.3892/mco.2020.2168